These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 32092597

  • 1. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
    [Abstract] [Full Text] [Related]

  • 2. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.
    PLoS One; 2016 Jun; 11(12):e0165721. PubMed ID: 27935989
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T, Shan L, Yang W, Zhou X, Shui R.
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K, Oba M, Ishikawa T.
    J Surg Res; 2020 Jun; 250():143-147. PubMed ID: 32044511
    [Abstract] [Full Text] [Related]

  • 5. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, Chen CK, Fan SC, Kuo SH, Huang CS.
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [Abstract] [Full Text] [Related]

  • 6. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672
    [Abstract] [Full Text] [Related]

  • 7. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
    Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    Cancer Res; 2019 Aug 15; 79(16):4258-4270. PubMed ID: 31213465
    [Abstract] [Full Text] [Related]

  • 8. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.
    Clin Breast Cancer; 2015 Feb 15; 15(1):80-5. PubMed ID: 25445419
    [Abstract] [Full Text] [Related]

  • 9. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W, Sardet C, Theillet C.
    Cancer Lett; 2024 May 01; 589():216820. PubMed ID: 38574883
    [Abstract] [Full Text] [Related]

  • 10. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines.
    Muguruma M, Teraoka S, Miyahara K, Ueda A, Asaoka M, Okazaki M, Kawate T, Kuroda M, Miyagi Y, Ishikawa T.
    Biochem Biophys Res Commun; 2020 Dec 10; 533(3):268-274. PubMed ID: 32958246
    [Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.
    Oncotarget; 2014 Jul 30; 5(14):5637-50. PubMed ID: 25026298
    [Abstract] [Full Text] [Related]

  • 12. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
    Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man YG, Brem RF, Fu SW.
    Breast Cancer Res; 2014 Sep 17; 16(5):435. PubMed ID: 25228385
    [Abstract] [Full Text] [Related]

  • 13. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.
    Nat Med; 2018 May 17; 24(5):628-637. PubMed ID: 29713086
    [Abstract] [Full Text] [Related]

  • 14. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan 01; 1866(1):165561. PubMed ID: 31639439
    [Abstract] [Full Text] [Related]

  • 15. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    Breast Cancer Res; 2020 Jul 25; 22(1):79. PubMed ID: 32711554
    [Abstract] [Full Text] [Related]

  • 16. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    Int J Cancer; 2019 Feb 15; 144(4):755-766. PubMed ID: 30259975
    [Abstract] [Full Text] [Related]

  • 17. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    BMC Cancer; 2016 Oct 19; 16(1):811. PubMed ID: 27756336
    [Abstract] [Full Text] [Related]

  • 18. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.
    J Clin Oncol; 2015 Jun 10; 33(17):1902-9. PubMed ID: 25847936
    [Abstract] [Full Text] [Related]

  • 19. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S.
    Clin Cancer Res; 2017 Jan 15; 23(2):514-522. PubMed ID: 28034904
    [Abstract] [Full Text] [Related]

  • 20. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.
    Gene; 2015 Feb 10; 556(2):163-9. PubMed ID: 25445393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.